NasdaqCM:VKTXBiotechs
A Look At Viking Therapeutics (VKTX) Valuation As Phase 3 Obesity Program Reaches Key Enrollment Milestones
Viking Therapeutics (VKTX) has moved deeper into late stage obesity drug development, completing enrollment in its Phase 3 VANQUISH-1 and VANQUISH-2 trials for injectable VK2735 and outlining plans for an oral Phase 3 program.
See our latest analysis for Viking Therapeutics.
The wider Q1 loss, as R&D spending ramped for Phase 3 obesity programs, appears to be weighing on sentiment in the short term, with a 1 month share price return decline of 8.98% and a year to date share price return...